Clinical Trial Update: Zoledronic Acid in the Prevention of Cancer Treatment Related Bone Loss in Postmenopausal Women Receiving Letrozole for Breast Cancer. [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating zoledronic acid to prevent cancer treatment-related bone loss in postmenopausal women with breast cancer receiving letrozole; the study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Zometa (Zoledronic acid)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Bone Loss, Breast Cancer | Phase 3 | Status: COMPLETED | Results posted: 2011-05-26